Incyte vs Iovance Biotherapeutics
Incyte (INCY) and Iovance Biotherapeutics (IOVA) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $23.4B
- Last close
- $114.63
- 12 months
- +12.6%
- Market value
- $3.19B
- Last close
- $6.90
- 12 months
- +216.5%
At a glance
- The biggest part of Incyte's revenue is JAKAFI (60%); at Iovance Biotherapeutics it is Amtagvi (83%).
- By market value, Incyte ($23.4B) is about 7.3 times Iovance Biotherapeutics ($3.2B).
- Over the last 12 months Incyte's share price moved +12.6% and Iovance Biotherapeutics's +216.5%; against the S&P 500 that is +6.9 points and +210.8 points.
- In their last fiscal years Incyte kept 25.0% of revenue as net income and Iovance Biotherapeutics -148.4%.
- In the last 90 days insiders reported 0 open-market purchases at Incyte and 0 at Iovance Biotherapeutics; members of Congress disclosed 0 trades in Incyte and 0 in Iovance Biotherapeutics.
- Next results: Incyte Feb 8, 2027, Iovance Biotherapeutics Feb 22, 2027.
How each one makes money: Incyte revenue · Iovance Biotherapeutics revenue
Share prices on one chart
Incyte and Iovance Biotherapeutics, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Incyte INCYNASDAQ · Biotechnology | Iovance Biotherapeutics IOVANASDAQ · Biological Products, (No Diagnostic Substances) | |
|---|---|---|
| Size and profitability | ||
| Market value | $23.4B | $3.19B |
| Revenue, last fiscal year | $5.14B | $264M |
| Net income, last fiscal year | $1.29B | −$391M |
| Net marginNet income as a share of revenue | 25.0% | -148.4% |
| Free cash flow | ||
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Incyte against
Common questions
How is Incyte different from Iovance Biotherapeutics?
Incyte (INCY) is in Biotechnology on NASDAQ, with $5.14B of revenue in its last fiscal year and a net margin of 25.0%. Iovance Biotherapeutics (IOVA) is in Biological Products, (No Diagnostic Substances) on NASDAQ, with $264M of revenue in its last fiscal year and a net margin of -148.4%. The biggest part of Incyte's revenue is JAKAFI (60%); at Iovance Biotherapeutics it is Amtagvi (83%). The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Incyte and Iovance Biotherapeutics compare in size?
Incyte has the larger market value: Incyte $23.4B and Iovance Biotherapeutics $3.19B, at the last close.
Whose share price rose more over the last 12 months, INCY or IOVA?
Over the last 12 months Incyte moved +12.6% and Iovance Biotherapeutics +216.5%. Past price moves say nothing about the future.
Which has had more insider buying, Incyte or Iovance Biotherapeutics?
Since 2006, Incyte insiders reported 503 open-market purchases against 31 for Iovance Biotherapeutics. These are counts of what was filed, not a view on either stock.
Do members of Congress trade INCY or IOVA?
In the last 12 months, members of Congress disclosed 0 trades in Incyte (INCY) and 0 in Iovance Biotherapeutics (IOVA).
When did insiders last buy INCY and IOVA?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Incyte pageIovance Biotherapeutics pageRare insider trades this weekAll comparisons
https://oqro.io/compare/incy-vs-iova







